局部晚期可切除食管癌新辅助免疫治疗进展  

Progress of neoadjuvant immunotherapy in the treatment of locally advanced resectable esophageal carcinoma

作　　者：黄俊俊 孙久贺 张士法[2] 刘洪锋 宋儒 王谦 陈立基 蔡海波[2] HUANG Junjun;SUN Jiuhe;ZHANG Shifa;LIU Hongfeng;SONG Ru;WANG Qian;CHEN Liji;CAI Haibo(Clinical Medical School of Jining,Jining,272000,Shandong,P.R.China;Department of Thoracic Surgery,Jining No.1 People's Hospital,Jining,272000,Shandong,P.R.China)

机构地区：[1]济宁医学院临床医学院,山东济宁272000 [2]济宁市第一人民医院胸外科,山东济宁272000

出　　处：《中国胸心血管外科临床杂志》2024年第7期1058-1065,共8页Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

基　　金：山东省医药卫生科技发展计划项目(2015WS0424)。

摘　　要：手术是治疗可切除食管癌的首选方案,但是在局部晚期食管癌中,单纯手术治疗效果并不理想,因此以手术为主的综合治疗是最佳方案。其中局部晚期可切除食管癌新辅助治疗已成为一种标准治疗手段,新辅助治疗包括新辅助化疗、放化疗、免疫治疗、靶向治疗等。随着免疫治疗在晚期食管癌的一线、二线治疗中都取得显著的疗效以及可接受的毒性,新辅助免疫治疗成为当下局部晚期可切除食管癌的研究热点。本文就新辅助免疫治疗在局部晚期可切除食管癌的最新研究进展以及存在的一些局限性进行阐述。Surgery is the preferred treatment for resectable esophageal cancer,but in locally advanced esophageal cancer,the effect of surgery alone is not ideal,so surgery-based comprehensive treatment is the best option.Neoadjuvant therapy has become a standard treatment in the treatment of locally advanced resectable esophageal cancer.Neoadjuvant therapy includes neoadjuvant chemotherapy,radiochemotherapy,immunotherapy,targeted therapy,etc.With the significant efficacy and acceptable toxicity of immunotherapy in the first-line and second-line treatment of advanced esophageal cancer,neoadjuvant immunotherapy has become a research hotspot of locally advanced resectable esophageal cancer.This article reviews the latest research progress and some limitations of neoadjuvant immunotherapy in locally advanced resectable esophageal cancer.

关 键 词：新辅助免疫治疗 局部晚期可切除食管癌 综述 

分 类 号：R735.1[医药卫生—肿瘤]